title: The role of mometasone furoate nasal spray in the treatment of adenoidal hypertrophy in the adolescents: a prospective, randomized, cross-over study.
abstract: Aim of this work is to find out whether the symptoms attributable to adenoid hypertrophy in adolescents may be treated with intranasal mometasone furoate (MF) application. To learn if adenoid hypertrophy in adolescents may decrease in size with intranasal MF. A prospective, double blind, randomized, cross-over study was conducted in 28 subjects (12-18 years) with adenoidal hypertrophy. Subjects used intranasal MF or placebo for a duration of 6 weeks with a wash out period of 3 weeks. Subjective symptoms and adenoid size were evaluated. At the initiation of the study, there was no significant difference between the mean symptom scores for any of the sinonasal symptoms between the two treatment groups. There was significant improvement in total subjective symptoms (nasal blockage, rhinorrhea, cough, snoring and disruption of quality of life scores) with MF compared with placebo. Analysis of the symptoms separately showed a significant positive effect of MF on all symptoms except for rhinorrhea. Nasal endoscopic evaluation failed to demonstrate any difference in the reduction of the adenoid size between the two groups. MF has significant advantage over placebo for the symptoms attributable to adenoid hypertrophy in adolescents.
authors: Tuzla State Hospital Otolaryngology Clinic, Istanbul, Turkey.
authors: Huseyin Baki
authors: HB
authors: Yilmaz
authors: Saban
authors: S
authors: Celebi
authors: Asli
authors: A
authors: Sahin-Yilmaz
authors: Cagatay
authors: C
authors: Oysu
mesh_terms: D000234:Adenoids / Q000473:pathology*; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D003371:Cough / Q000188:drug therapy / Q000209:etiology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006984:Hypertrophy / Q000150:complications / Q000188:drug therapy*; D008297:Male; D000068656:Mometasone Furoate; D015508:Nasal Obstruction / Q000188:drug therapy / Q000209:etiology; D059085:Nasal Sprays; D009929:Organ Size; D011244:Pregnadienediols / Q000627:therapeutic use*; D011446:Prospective Studies; D012913:Snoring / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D059085:Nasal Sprays; D011244:Pregnadienediols; D000068656:Mometasone Furoate
references: Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006286
references: 18646145
references: Neuroimmunomodulation. 2009;16(5):353-62
references: 19571596
references: Pediatrics. 2007 Jun;119(6):e1392-7
references: 17533178
references: Pediatrics. 1995 Mar;95(3):355-64
references: 7862473
references: Int J Pediatr Otorhinolaryngol. 2010 Jul;74(7):773-6
references: 20430451
references: J Otolaryngol Head Neck Surg. 2008 Aug;37(4):469-73
references: 19128578
references: Pediatrics. 2003 Mar;111(3):e236-8
references: 12612277
references: Int J Immunopathol Pharmacol. 2007 Oct-Dec;20(4):833-6
references: 18179756
references: Int J Pediatr Otorhinolaryngol. 2006 Apr;70(4):609-12
references: 16157389
references: Braz Oral Res. 2006 Jan-Mar;20(1):70-5
references: 16729178
references: Int J Pediatr Otorhinolaryngol. 2008 Aug;72(8):1171-5
references: 18499270
references: Arch Otolaryngol Head Neck Surg. 1986 Aug;112(8):873-6
references: 3718695
references: Dtsch Arztebl Int. 2012 Apr;109(15):276-81
references: 22567063